Dr Heemskerk participated, and as member of MEDVIA and in the framework of the PASSION-HF project, the Smart Health Technologies in Medical Diagnostic and Treatment forum in Iasi, Romania. https://medvia.be/members-invited-to-international-mission-to-romania-for-smart-health-technologies/
RIMS, as a company based in Flanders, has joined the Flemish Health cluster (https://medvia.be/domains/digital-technology/). MEDVIA is an industry driven network, set up as a public private partnership with the Flemish government, with the aim to stimulate innovations in healthcare. All the members are committed to jointly support innovation for better health at the crossroads of medical biotechnology, medical technology, and digital technology.
RIMS has entered as a full partner into the PASSION-HF consortium of 11 partners in 6 EU countries, which is co-funded by the European InterReg North-West Europe program (https://www.nweurope.eu/programme-2021-2027/). In this PASSION-HF project, the consortium will develop an integrated eHealth product enabling self-care of chronic HF including self-prescription of medication. It will include novel features such as a decision support engine, interactive physician avatar interface, serious gaming tools and self-learning feedback system. Our role is to further strengthen the product development and develop a joint commercialization strategy to bring DoctorME closer to market readiness. More details on the aims, results, financial support from this Interreg NWE project start and end dates, and the number and origin of partners are all described on: https://www.nweurope.eu/projects/project-search/passion-hf-patient-self-....
More detailed information, a video, publications, newsletters etc can be found on https://www.doctor-me.eu/index.html.
For the third year in a row, Belgium has been ranked the number one country in Europe for biotech! Belgium is consistently included in the top five countries on a number of measures. But when it comes to the total market value of all public biotech companies in Europe, Belgium really takes the cake with a huge 24% slice. Furthermore, despite pressure from the pandemic, the value of Belgian biotech companies has increased by no less than 56% in the past year to €42 billion, putting 2020 on course to be a record-breaking year in a positive way. The great news was presented by KBC Securities at the virtual State of the Union organized by flanders.bio and VIB for this year’s Knowledge for Growth. With such a fantastic ecosystem of innovation, experience and support, we can't say we're too surprised. However, we should all take this moment to be very proud of our small country, which punches well above it's weight when it comes to life sciences! See full article on the BioVox website: https://biovox.eu/belgium-the-number-one-biotech-country-in-europe/
The Association EUPLANTCROPP, which will support and maintain the research infrastructure on the long term, was founded on the 25th of July 2017 at the notary in Leiden.
To celebrate this official launch, a short video was produced which explains the reasons to join EUPLANTCROPP, the importance of it for innovation in Europe, and the expected main achievements the next five years.
EUPLANTCROPP - EUropean PLANT metabolites platform of CROP Protection
Submitted under the call INFRAIA-02-2017, Research and Innovation Action, it’s a 4.0 research infrastructure providing an eco-metabolomics approach to crop protection.
The proposal has succeeded the first step of evaluation and has been submitted to the final evaluation.
EUPLANTCROPP brings together and integrates top-level regional, national, and European research infrastructures and communities to provide an innovative research platform for scientists from companies and academia to take an eco-metabolomics approach to sustainable plant protection. Scientists, companies, and especially SMEs, will have access to the best facilities in Europe and benefit from the integrated know-how of this unique R&D platform to develop innovative products and methods of crop protection.
EUPLANTCROPP will function as the crystallisation point of a lively, interacting international Community of Knowledge committed to advance sustainable crop protection. We expect that in the next ten years the Community will grow to encompass all relevant research communities and infrastructures, breeding companies, farmers, producers of bio-pesticides, regulatory authorities and other key stakeholders in Europe.
A legal entity, in the form of a non-profit Association, will be set up with the main objective of maintaining, extending and exploiting the research infrastructure at the end of the Horizon 2020 project. It will take over the deliverables of the project and facilitate further R&D-projects with companies and academia to maintain the joint facilities and sustain the Community beyond the H2020 project. RIMS is one of the three founding partners of the Association, and will put its expertise and global network to further exploitation and develop sustainable business cases.
RIMS attending EARMA Conference in Malta – April 2017 - presentation in session on Global Development together with Mr Robert Burmanjer (DG DEVCO- European Commission) and SARIMA from South Africa: key points of discussion focus on added value of global academic cooperation for achieving the sustainable development goals. RIMS presented the impact achieved in the RIMI4AC project we did together with SARIMA in Africa to enable capacity building in academia across the continent.
QM4A visits Uganda and Kenya– monthly visits in 3Q 2016 - 1Q2017- meetings with a whole range of stakeholders, including the Ministry of Health, several global multinationals (GE Health, Siemens, big pharma), and academia to build up support/partnerships for our QM4A platform.
New company formed: QM4A (11-01-2017)
QM4A (Quality Medicines for All – www.qm4a.eu) is a new management company with offices in Ireland, Belgium, UK and France, with the objective to strengthen health care systems in LMICS in Africa. An experienced team, including dr Frank Heemskerk from RIMS, after 6 years feasibility studies/ discussions with stakeholders and careful preparations, has now reached a point where an international platform is developed to support several key actions to strengthen access to quality medicines. With a signed Letter of Support from the prime Minister of Uganda, we have now full support from the Ministry of Health, UNIDO, UN, University of Makarere and other local key stakeholders to roll out a 7 year program, which includes establishment of 4 Centers of Excellence.